Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database.

Fiche publication


Date publication

mai 2015

Auteurs

Membres identifiés du Cancéropôle Est :
Pr QUANTIN Catherine, Pr BONNIAUD Philippe


Tous les auteurs :
Abdulmalak C, Cottenet J, Beltramo G, Georges M, Camus P, Bonniaud P, Quantin C

Résumé

Haemoptysis is a serious symptom with various aetiologies. Our aim was to define the aetiologies, outcomes and associations with lung cancer in the entire population of a high-income country. This retrospective multicentre study was based on the French nationwide hospital medical information database collected over 5 years (2008-2012).We analysed haemoptysis incidence, aetiologies, geographical and seasonal distribution and mortality. We studied recurrence, association with lung cancer and mortality in a 3-year follow-up analysis. Each year, approximately 15 000 adult patients (mean age 62 years, male/female ratio 2/1) were admitted for haemoptysis or had haemoptysis as a complication of their hospital stay, representing 0.2% of all hospitalised patients. Haemoptysis was cryptogenic in 50% of cases. The main aetiologies were respiratory infections (22%), lung cancer (17.4%), bronchiectasis (6.8%), pulmonary oedema (4.2%), anticoagulants (3.5%), tuberculosis (2.7%), pulmonary embolism (2.6%) and aspergillosis (1.1%). Among incident cases, the 3-year recurrence rate was 16.3%. Of the initial cryptogenic haemoptysis patients, 4% were diagnosed with lung cancer within 3 years. Mortality rates during the first stay and at 1 and 3 years were 9.2%, 21.6% and 27%, respectively. This is the first epidemiological study analysing haemoptysis and its outcomes in an entire population. Haemoptysis is a life-threatening symptom unveiling potentially life-threatening underlying conditions.

Référence

Eur Respir J. 2015 May 28. pii: ERJ-02182-2014.